Thursday, 9 April 2020

Global Gene Panel Market 2020 – Investment Strategy, Outlook and Key Development till 2023

Market Scenario
The increasing prevalence of chronic diseases such as cancer, genetic diseases, and rare diseases, increase in adoption of genetic testing, rising company initiatives, technological advancements, need for efficient prenatal diagnosis, and increasing health awareness are estimated to drive the market during the forecast period. However, factors such as expensive tests, inaccuracy in results, and security concerns of the genes are estimated to restrain the market growth during the forecast period.
Global Gene Panel Market size is expected to register a CAGR of 12.16% to reach USD 4,347.32 Million by 2025.
Segmentation
The global gene panel market is segmented on the basis of product and service, technique, design, application, and end-user. The gene panel market, by product and service, is segmented into test kits and testing services. The global gene panel market by technique is segmented into the amplicon-based approach and hybridization-based approach. The design segment is segmented into predesigned gene panels and customized gene panels. On the basis of application, the market is categorized into cancer risk assessment, pharmacogenetics, diagnosis of congenital disorders, and other applications. The cancer risk assessment segment is further sub-segmented into syndrome-specific gene panels, high-penetrance gene panels, high and moderate-penetrance gene panels, and comprehensive cancer risk panels. On the basis of end-user, the market is categorized into hospitals, diagnostic laboratories, research and academic institutes, and pharmaceutical and biotechnology companies.
Key players
Some of the key players for the global gene panel market are Thermo Fisher Scientific (US), F. Hoffmann-La Roche AG (Switzerland), Illumina, Inc., BGI (China), Agilent Technologies (US),  Integrated DNA Technologies (IDT) (US), Eurofins Scientific (US), QIAGEN (Germany), GENEWIZ, Novogene Corporation (China), Personalis (US), GATC Biotech AG (GATC Biotech) (Germany), ArcherDx (US), GeneDx., CENTOGENE AG, and others.
Regional Market Summary
The Americas dominates the global market for gene panel. The increase in the patient pool for chronic diseases, government initiatives for the development of cancer treatment, and presence of strong market players such as Thermo Fisher Scientific drive the market growth in this region. Europe (the U.K., Belgium, France, and the Netherlands) is second in the market owing to the increasing research and development activities for cancer and congenital diseases. Also, the high occurrence rate of cancer in Europe influences the market growth in Europe. According to WHO, there are 3.7 million cases of cancer in Europe every year. Furthermore, Germany is predicted to dominate the European market as there were 2, 24,089 number of deaths due to cancer in 2014. Also, technological advancements coupled with an early diagnosis of cancer is likely to drive market growth for gene panel in Germany. Asia Pacific is expected to observe growth for the global gene panel market owing to the growing prevalence of cancer and increasing health expenditure. The Middle East and Africa with the presence of low-income countries, low healthcare expenditures, and stringent government regulations accounted for the least market share.

Defibrillators Pads Market By Key Vendors, Regions, Trends with Industry Study & Forecast to 2023

Key Players
Medtronic, Cardiac Science Corporation, Koninklijke Philips N.V., Boston Scientific Corporation, Stryker Corporation, Cardinal Health, Biotronik SE & Co. KG, Defibtech, LLC., and  Mindray Medical are Some of the key players in the Defibrillators pads market.
Market Scenario:
Defibrillation is a procedure that involves the delivery of an electric shock to the heart which causes depolarization of the heart muscles and re-establishes normal conduction of the heart’s electrical impulse. To increase the efficacy of automated defibrillator, pads are attached to them which directly touches victim’s chest and delivers a shock to them. The gel present in the pads acts as a bonding agent and helps the AED pads to adhere firmly to the victim’s skin thus, increasing its efficacy.
Defibrillators Pads Market size is expected to register a CAGR of 5% during the forecast period.
The global defibrillators pads market is majorly driven by the increasing number technical advanced devices, increasing number of regulatory approvals, rising geriatric population, abuse of alcohol, the high prevalence of cardiac diseases such as ventricular fibrillation, ventricular tachycardia, and cardiac arrhythmias, and growing penetration of key market players. Furthermore, the increasing awareness of healthcare, favorable reimbursement policies, increasing innovations in research and development of medical devices, as well as rising average income of individuals are fueling the market growth. However, factors such as high cost of defibrillators pads and complicated and costly surgical procedures involved in implantation defibrillators are likely to hamper the growth of the market. Lack of proper healthcare infrastructure, as well as awareness regarding diseases such as cardiac arrhythmia and tachycardia in middle-income countries, are major challenges to the market growth.
Market Segmentation:
The global defibrillators pads market is segmented on the basis of product, age group, distribution channel, and end-user. According to products, the market is segmented into manual external, manual internal, automatic external, and others
Considering the age group, the market is segmented into pediatric defibrillator pads and adult defibrillator pads.
According to the distribution channel, the market is segmented into online pharmacy, retail pharmacy, hospital pharmacy, and others.
On account of end-user, the market is segmented into pre-hospital services, hospitals & clinics, alternate care facilities, public access market, and home healthcare services market.
Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. Americas region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
Regional Analysis:
Americas is the global leader for defibrillators pads market owing to increasing prevalence of cardiovascular diseases among adults and older population and rising more elderly population which increases the vulnerability to hypertension and obesity issues which are indirect causes of heart disease.  Additionally, factors such as increasing government initiatives and funding for research, development in advanced medical treatment options, and rising demand for technologically advanced treatment are likely to enhance the growth of defibrillators pads market in the American region. For instance, according to American Heart Association, in 2014, around 31% of the deaths in the U.S. were due to cardiovascular disorders. Similarly, according to stats presented in reports published by the Centers for Disease Control and Prevention,  heart disease is the most common cause of death and accounted for the death of about 366,000 people in 2015. This growing rate of cardiovascular disorders is expected to have a direct effect on the growth of the defibrillators pads market as it finds whole and sole application in cardiovascular disorders. 
Europe is the second largest market and holds a healthy share in the global defibrillators pads market. The European market is expected to grow at a sturdy growth rate during the forecast period due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure along with growing need for better healthcare infrastructure and government initiatives of healthcare reform. For instance, according to 2017 statistics presented by the European Society of Cardiology, there were more than 6 million reported new cases of cardiovascular diseases in the European Union and more than 11 million in Europe as a whole. Additionally, every year 15% of deaths in Europe occur due to cardiovascular diseases. Hence cardiovascular disease being one of the major concern in Europe contributes significantly to the market growth of this region. Additionally, Europe spent around 210 Euros in 2015 for treatment of cardiovascular disorders. This rising healthcare expenditure due to cardiovascular disorders is expected to have a positive impact on the defibrillators pads market. Developed countries such as the U.S. and the U.K. are making it compulsory for certain sports arenas, schools, government facilities, and institutes to store and maintain Automated External Defibrillators (AEDs), as unavailability of defibrillators is the most common cause of sudden cardiac arrest.
The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, United Arab Emirates is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers.
Asia Pacific is expected to be the fastest growing market. According to report published by the United Nations in 2015; between 2015 and 2030, the number of older persons aged 60 years or over in the world is predicted to grow by 56 %, out of which 66% of the older population would reside in Asia-Pacific regions. This makes the region prone to metabolic disorders that would further aid the chances of cardiovascular diseases. Owing to the huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, favorable insurance and reimbursement policies, and key players such as Boston Scientific Corporation and Medtronic have been setting up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia. This is accelerating the growth of the defibrillators pads market. Moreover, raising adaption of western culture has led to increasing sedentary lifestyle due to work culture, addiction to alcohol and smoking, consumption of fast foods which are the indirect causes of cardiovascular diseases and rise in the standard of living in the region also contributes to defibrillators pads market growth. However, on the other hand, factor such as lack of skilled healthcare professionals may slow down the market growth during the forecast period. For instance, according to the Global Burden of Disease Report in 2016, heart diseases is expected to lead to 1.7 million deaths in India. This rising prevalence of heart diseases is expected to propel the growth of the market.

Top Trends in Coronary Stent Market 2020 – 2023 by Growth Factors and Industry Players Overview

Coronary Stent Market Research Report: By Type (Bare-Metal Stents, Drug-Eluting Stents, and Bio Absorbable Stents), by Mode of Delivery (Balloon-Expandable Stents and Self-Expanding Stents), by End-User (Hospitals & Clinics) - Global Forecast Till 2023
Coronary stents are small stretchy tube-like devices used to expand the arteries of the patient in order to prevent blockage. A coronary stent is inserted into the artery of a patient suffering from a coronary disease due to the build-up of plaque. It is used for widening the narrowed arteries, and it helps in reducing chest pain and the chance of heart attack
The global coronary stent market is mainly driven by the high prevalence of heart-related diseases and huge demand for diagnosis and treatment methods. Additionally, the increasing availability of diagnostic services for coronary heart diseases also fuels the growth of the market. Moreover, favorable reimbursement policies are likely to boost the market growth.
Many private and government insurance organizations are present in developed countries. Over 50 private insurance companies are present in the U.S. The policies cover more than 75% of the cost of the devices and treatment. For instance, under the Medicare plan in the U.S., if the average cost of three stents is approximately USD 10,000, then USD 7,500 is reimbursed. Additionally, in developed countries such as the U.K., Canada, and Germany, other similar reimbursement policies are available. On the other hand, alternative treatment methods for coronary arteries disease and numerous cases of product recalls may hamper the market growth.
The global coronary stent market is expected to have a CAGR of 7.8% during the forecast period.
Intended Audience
  • Medical Device Manufacturers
  • Medical Device Suppliers
  • Medical Research Laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Potential Investors
Segments  
The global coronary stent market is segmented on the basis of type, mode of delivery, material, and end-user.
On the basis of type, the market is segmented into bare-metal stents, drug-eluting stents, and bio absorbable stents.
On the basis of mode of delivery, the market is segmented into balloon-expandable stents and self-expanding stents.
On the basis of material, the market is segmented into metallic stents, cobalt chromium, platinum chromium, nickel titanium, stainless steel, and others.
On the basis of end-user, the market is segmented into hospitals and clinics, cardiac centers, ambulatory surgical centers, and others.
Regional Analysis of the Global Coronary Stent Market                       
The American coronary stent market is segmented into two regions, namely, North America and South America. North America, being the largest market, is mainly driven by the increasing patient population suffering from coronary heart disease, growing investment in healthcare, and increasing geriatric population. Furthermore, the U.S. is the largest market in North America owing to the presence of a large number of market players manufacturing coronary stents and the increasing awareness about risk factors for the coronary heart disease. Canada is expected to be the fastest growing market which is driven by the overall increasing demand for medical devices with progress in coronary stent devices. South America is expected to be the fastest growing market due to technologically advanced devices for diagnosis and the increasing demand for treatment options of the coronary heart disease.
The European coronary stent market exhibits a positive growth with an increasing emphasis on the diagnosis of heart diseases and other related diseases. Moreover, Germany and the U.K. are the major contributors to the growth of the market. Additionally, the increasing expenditure in healthcare by major countries in Europe also accelerates the growth of the market.  
Asia Pacific is expected to be the fastest growing market whose growth is attributed to the increasing burden of cardiovascular diseases and increasing focus on early diagnosis and treatment of heart diseases. Furthermore, other factors contributing to the growth of the market are lifestyle changes, the influence of western culture among adults, and addiction to smoking. Additionally, the increasing environmental pollution and exposure to harmful chemicals also attribute to the growth of the market.
The Middle Eastern and African market for coronary stents exhibits a steady rise with an increase in the number of healthcare facilities providing treatments for chronic conditions and the flourishing growth of the medical device sector especially diagnostic devices. In the African region, the awareness about the coronary heart disease is increasing the growth of the market.
Key Players in the Global Coronary Stent Market        
Some of the key players in this market are BIOTRONIK SE & Co. KG (Germany), B. Braun Melsungen AG (Germany), Terumo Corporation (Japan), Medtronic plc (Ireland), MicroPort Scientific Corporation (China), Meril Life Sciences Pvt. Ltd. (India), Vascular Concepts (India), and Translumina GmbH (Germany), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.),STENTYS SA (France), Biosensors International Group, Ltd. (Singapore), Kyoto Medical Planning Co. Ltd. (Japan), Elixir Medical Corporation (U.S.), and Reva Medical Inc. (U.S.), and others.

2020 Glioma Diagnosis and Treatment Market Growth Rate Research Report, Historical Analysis, Opportunities, Business Strategy and Potential of Industry 2023


Market Scenario
A Glioma is a type of tumor that originates in the brain and is also known as a primary brain tumor. There are numerous types of gliomas which are entitled based on the origin of the cell type including oligodendrogliomas, astrocytoma, ependymomas, and glioblastoma. Nearly 33 percent of all brain tumors are gliomas. These originate in glial cells surrounding the neurons in the brain.
Global Glioma Diagnosis and Treatment market is expected to grow at a CAGR of approximately 10.1% during the forecast period, 2017–2023.

According to the American Brain Tumor Association, more than 79,000 new cases of primary brain tumors were diagnosed in 2017 with 24.7% of those being gliomas.


Brain tumors are one of the prominent causes of cancer among children and teenagers. Glioma is the most common type of brain tumor which accounts for approximately half of all the astrocytoma. The increasing occurrence of glioblastoma over the years is responsible for the growth of the glioma diagnosis and treatment market. The upcoming drug launches and developments in research are instrumental for the growth of the market. In addition, the current unmet need is expected to drive the gliomas industry over the forecast period. Changing financial demands and access to healthcare facilities are some of the factors that are constraining the market growth.


Astrocytoma is the most common types of glioma diagnosed worldwide, as more than 30% of all the diagnosed cases with brain tumors are astrocytoma. These types of tumors are not curable as they spread easily through normal brain tissue. The American Brain Tumor Association has evaluated that around 7% of all the primary brain tumors represent astrocytoma.
The expanding market for the treatment of brain cancer-associated symptoms, the increasing prevalence of brain cancer, and innovations in drug delivery to brain cancer cells are some of the key factors augmenting the demand in the global glioma diagnosis and treatment market. Furthermore, the introduction of novel therapies coupled with various organizations generating awareness and increasing geriatric population are factors driving the growth of the global glioma diagnosis and treatment market.

Key Players
Some of the key players in the global glioma diagnosis and treatment market are Thermo Fisher Scientific Inc. (U.S.), Emcure Pharmaceuticals Ltd. (India), Sigma-Aldrich Co. (U.S.), Pfizer Inc. (U.S.), Taj Pharmaceuticals Limited (India), Novartis International AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), GE Healthcare (U.S.), Siemens Healthineers (U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Merck & Co., Inc. (U.S.), F. Hoffmann-Le Roche AG (Switerland), Arbor Pharmaceuticals, LLC (U.S.), Sun Pharmaceutical Industries, Ltd. (India), Amneal Pharmaceuticals. LLC (U.S.), AstraZeneca (UK), Carestream Health (U.S.), Hitachi Medical Corporation (U.S.), and others.
Segmentation
Geographically, the Americas glioma diagnosis and treatment market is segmented into two major regions, namely, North America and South America.
North America accounted for the largest share of the global gliomas industry in 2016, and the trend is expected to continue over the projected period. Moreover, it is anticipated that about 80,000 new cases will be registered related to brain tumors in the year 2017 which includes 26,000 primary malignant brain tumors.
The Americas glioma diagnosis and treatment market is segmented on the basis of type, diagnosis, treatment, grade, location, and end-user.
Regional Analysis
The global glioma diagnosis and treatment market consist of four major regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
Growing medical tourism and prevalence of metastatic tumors that require surgical procedures are favoring the growth of the market in the Middle East and Africa. In addition, the development of drug delivery technologies, a combination of modern diagnostic techniques, and increasing awareness of various types of brain tumors are similarly supporting the growth of this market.
The Americas dominates the market owing to the key players domiciled in these regions coupled with the increasing incidences of brain tumor, rising awareness among people, and increasing healthcare expenditure. Brain tumor is the third most common types of cancer in adults in North America. According to the North American Brain Tumor Coalition over 44,500 people in the U.S. were diagnosed with a primary tumor in the brain in 2014. Thus, the increasing incidences of primary brain tumor support the growth of the malignant glioma treatment in North America.  
Asia Pacific is estimated to be the most lucrative market for gliomas due to the increasing occurrence of brain tumors in Asia Pacific countries such as China and others. The growth in the Asian market is fueled by the expanding healthcare infrastructure and presence of untapped market opportunities in this region. This region is considered as an emerging market owing to the increasing number of manufacturers coupled with the increasing market penetration.

Neuroendoscopy Market By Key Vendors, Regions, Trends with Industry Study & Forecast to 2023

Market Scenario:
Neuroendoscopy is characterized as a minimally-invasive surgical procedure which is extensively utilized to remove tumors. The excision occurs via small holes present in the skull, i.e., through the mouth or nose. In neuroendoscopy procedures, a small telescopic device equipped with a high-resolution video camera and an eyepiece is used. This gives the neurosurgeons, an ability to navigate and effectively access the parts of the brain that could not be addressed by traditional surgery. Some of the other advantages of neuroendoscopy include fast recovery, minimal scarring, and others.
The increasing prevalence of brain tumors is a major driver for the market growth. According to a study published by the Neuro-Oncology Journal in 2015, the global incidence rate for all types of brain tumors was estimated to be about 10.82 per 100 000 persons.
The increasing prevalence of brain tumors, increasing demand for minimally invasive surgical procedures, growing geriatric population, and favorable reimbursement policies are estimated to drive the global neuroendoscopy market growth, during the forecast period. However, a dearth of physicians and the high cost of neuroendoscopy procedures and equipment are projected to restrain the market growth during the forecast period.
Global Neuroendoscopy Market is expected to grow at an approximate CAGR of 5.2% during the forecast period.
According to the National Institute of Health in 2016, the global geriatric population is estimated to be more than triple from 2015 to 2050, i.e., it is projected to grow from 126.5 in 2015 million and reach 446.6 million by 2050. However, a shortage of physicians and high cost for neuroendoscopy procedures and equipment are projected to restrain the market growth during the forecast period. The Association of American Medical Colleges in 2016 stated that the demand for physicians continued to grow at a higher rate, exceeding the supply. The projected total physician shortfall by 2025 is estimated to be in between 61,700 and 94,700.
Key players
The key players in the global neuroendoscopy market are KARL STORZ (Germany), B. Braun (Germany), Ackermann Instrumente (Germany), Adeor Medical (Germany), Hangzhou Hawk Optical Electronic Instruments (China), Machida Endoscope (Japan), Tonglu Wanhe Medical Instrument (China), Schindler Endoskopie (Germany), Clarus Medical (U.S.), LocaMed (U.K), Visionsense Corporation (U.S.), Olympus Corporation (Japan), Zeiss International (Germany), Stryker (U.S.), Medtronic (U.S.), and others.
Segmentation
The global Neuroendoscopy market is segmented on the basis of product, application, usability, and end-user.
On the basis of products, the market is segmented into rigid neuroendoscopes and flexible neuroendoscopes. The rigid neuroendoscopes segment is sub-segmented into rigid video scopes and rigid fiberscopes. On the basis of application, the market is categorized into transnasal neuroendoscopy, intraventricular neuroendoscopy, and transcranial neuro-endoscopy. On the basis of usability, the market is segmented into reusable neuroendoscopes and disposable neuroendoscopes. On the basis of end-users, the market is segmented into hospitals, clinics, medical research centers, and others.
Regional Analysis
The Americas dominates the global neuroendoscopy market. Factors such as the increasing prevalence of brain tumors, the presence of a well-developed healthcare sector, and huge health care expenditures within the region drive the market growth within the region. Moreover, the presence of key players such as Stryker and Medtronic, besides others and the growing geriatric population within the region fuel the market growth.
Europe stands second in the global neuroendoscopy market due to the increasing demand for minimally invasive surgeries, rising availability of funds for research and development, and a huge patient population. According to the Cancer Research U.K., the total number of new cases for brain tumor was estimated to be about 11,432 in 2015.  
Followed by Europe, Asia Pacific stands third in the global neuroendoscopy market. Moreover, the region is projected to be the fastest growing region in the global market. This can be attributed to the presence of developing economies such as China, growing patient population, developing healthcare sector, and increasing per capita healthcare expenditures. Additionally, favorable government policies support the market growth. Medical tourism and rising geriatric population are estimated to fuel the market growth. According to the Indian Brand Equity Foundation, the medical tourism industry in India is estimated to grow rapidly and reach USD 9 billion by 2020.
The Middle East and Africa holds the least share in the global neuroendoscopy market due to the presence of poor economies, stringent government policies, lack of awareness, low per capita income, and poor availability of healthcare services, especially within the African region. A majority of the neuroendoscopy market within the region is held by the Middle East due to the presence of a well-developed healthcare sector and huge healthcare expenditure.

Picture Archiving and Communications Systems Market Global Analysis, Size, Share, Trends, And Forecast 2020 to 2023

Market Scenario:
Radiology imaging solutions have generated a significant return on its healthcare IT investment by implementing Exa’s Voice Recognition in place of traditional transcriptionists, and their productivity has increased by 400%.           
Picture Archiving and Communication System (PACS) is a modality of the medical imaging technology used specifically for image transmission from the site of image acquisition to other locations. The technology is convenient to access multiple modalities such as radiographs, CT scan, MRI, ultrasound, and others.
It is noted that the increasing prevalence of chronic diseases and the growing geriatric population are the key factors driving the PACS market. The increasing burden of chronic diseases has been observed in different parts of the world. Population in the low socio-economic group is mostly found to get affected by these chronic diseases. According to the report published in the Centers for Disease Control and Prevention (CDC) in 2017, nearly 92.1 million adults are dealing with at least one type of cardiovascular disease. The prevalence of type-2 diabetes, obesity, and cardiovascular diseases has increased rapidly in the recent years, suggested by a study published in the BMC Public Health in 2017.
Various other factors such as supportive investments and funds provided by government and private bodies, rising demand for early diagnosis, technological advancements in the medical imaging devices, rising incidence of cancer, improving regulatory framework, growing research funding, unmet medical needs, rising competition among market players, and increasing government assistance are continuously contributing to the growth of the global PACS market.
Despite these drivers, there are some issues associated with the PACS market. The high cost associated with the technology, lack of healthcare insurance, lack of awareness, and poor healthcare system in low- and middle-income countries may hamper the growth of the market.
It is estimated that the Picture Archiving and Communications Systems (PACS) market growth is expected to boost at a CAGR 7.0% during the forecast period of 2017–2023.
Key Players
Some of the key players in the global Picture Archiving and Communications Systems (PACS) market are Advanced Data Systems, Agfa-Gevaert N.V., Allscripts Healthcare Solutions, Inc., ALTA VISTA TELERADIOLOGY, Argus Radiology, Avreo, Inc., Brit Systems, Comarch SA, Cybernet Medical Corporation, FujiFilm Medical Systems, GE Healthcare, Global Diagnostics, INFINITT Healthcare, Konica Minolta Healthcare Americas Inc., McKesson Corporation,Inc., ONRAD, Inc., Pacshealth, LLC, PERFECT IMAGING, LLC, RamSoft, Inc., Radiology Imaging Solutions, Scimage, Inc., Sectra Imtec AB, Sectra Imtec AB, Siemens Healthineers, Singular Medical Technologies, StatRad, LLC, Telediagnostics Services Pvt. Ltd., Telerad Tech Private Limited, Virtual Radiology (vRAD), and others
Segmentation
The global Picture Archiving and Communications Systems (PACS) market is segmented on the basis of type, component, imaging type, delivery mode, and end-user.
On the basis of the type of imaging type, the market is classified as Magnetic Resonance Imaging (MRI), Computed Tomography (CT), nuclear imaging, X-ray, and ultrasound.
On the basis of end-user, the market is classified as hospitals and clinics, healthcare centers, imaging centers, diagnostic centers, clinical research institutions, and others.
On the basis of delivery mode, the market is classified as cloud-based (SAAS) delivery mode, web-hosted (On-Demand) delivery mode, and on-premise mode.
On the basis of type, the market is classified as oncology PACS, cardiology PACS, dental PACS, orthopedics PACS, and others.
On the basis of components, the market is classified as hardware, software, and services. The hardware segment is further classified as access devices, peripherals, servers, storage devices, and networking devices. The services segment is further classified as consulting, implementation services, post-sales and maintenance services, and training services.
Regional Analysis
Asia Pacific is the fastest growing Picture Archiving and Communications Systems (PACS) market owing to a huge patient pool, increasing demand for diagnosis, and development in the healthcare IT sector. According to IBEF, the Healthcare Information Technology (IT) market was valued at USD 1 billion in 2016 which is estimated to grow 1.5 times by 2020.
The Americas dominates the Picture Archiving and Communications Systems (PACS) market owing to the rising demand for early diagnosis, rising prevalence of chronic diseases, well-developed technology, high healthcare expenditure, and the presence of leading players. Owing to the rising demand for imaging devices, various market players are coming up with advanced technology. For instance, on March 26, 2018, Singular Medical Technologies (SMT), the U.S. based technology company announced two new additions to its PACStation suite of products. The PACStation-GO is a fully functional reading workstation, with two full-size diagnostic monitors and is completely portable.
Europe holds the second position in the Picture Archiving and Communications Systems (PACS) market. It is expected that the funding towards research and development expenditure and increasing competition among marketers are likely to drive the European market.
The Middle East and Africa holds the lowest share of the global Picture Archiving and Communications Systems (PACS) market due to low development, lack of technical knowledge, and poor medical facilities.

Wednesday, 8 April 2020

MEA Anti-Fungal Agents Market Worldwide Key Players Forecasts By Revenue, Growth Rate Till 2022

Anti-fungal agents are used in the treatment of infections caused by fungus. According to global action fund for fungal infection, globally, over 300 million people of all ages suffer from a serious fungal infection every year. The market drivers include rising prevalence of fungal infections, rising awareness, rise of immunity deficient population such as geriatrics, rise in exposure to infectious agents due to environmental factors such as pollution especially by particulates and agriculture residues and climatic conditions such as humidity and temperature, occupational hazards such as Jock itch, crowding etc. Growth of fungal infection due to off label use of broad spectrum antibiotics is a prime factor for the growing market for anti-fungal agents.
The market restraints include rising resistance to anti-fungal agents, use of air filters and air conditioning, excellent spectrum and efficacy of Azole class of anti-fungal agents, loss of patents and genericitization etc. Competition by generics is exceptionally strong and generics account for roughly 50% of total sales for anti-fungal agents. The market penetration is very easy as there has been loss of patents of block buster drugs. Over the counter drugs are an important reasons for the growth of anti-fungal agents market.
The Middle East and Africa anti-fungal agents market is segmented into therapeutic indication which is further segmented into aspergillosis, dermatophytosis, candidiasis and others. On the basis of drug class the sub-segments are azoles, pyrimidines, echinocandins, polyenes, allylamines, and others. By route of administration the market is further divided into oral, local and others.
The market for Middle East and Africa anti-fungal agents is extremely fragmented with a number of small and big players. The market is also affected by substandard and counterfeit products especially in poorer regions of Africa with weak regulatory framework. Product development especially for resistant fungal infections has the highest potential among all the strategies.
Key Players:
The major participants of this market are: Novartis AG, Pfizer, Inc., Sanofi-Aventis, Merck & Co., Inc., Enzon Pharmaceuticals, Inc., Bayer AG, Astellas Pharma, Inc., GlaxoSmithKline plc, Abbott, Sigma-Aldrich and others
Middle East and Africa Anti-Fungal Agents Market:
The Middle East and Africa Anti-fungal agents market has been evaluated as a growing market and it is expected that the market will grow at a moderate CAGR in future. The Middle East and Africa Anti-fungal agents market is expected to grow with CAGR of ~3.5% during the forecast period. The growth will be primary channeled by the need of unmet medical needs, rising incomes of the population and the high prevalence of fungal infection in Africa. Environmental factors such as high humidity and temperature along with the rich biodiversity of Africa will positively affect the market growth of anti-fungal agents.
Regional Analysis:
Depending on geographic region, anti-fungal agents market is segmented into following countries: UAE, Egypt, Saudi Arabia, Kuwait, Qatar and Oman. UAE is the largest market followed by Egypt. However the future market will be led by the poor developed parts of Africa due to large unmet needs and the seasonal climatic conditions of Africa. The eastern parts of Africa is expected to have greater market share as compared to the hot and dry western coast.
Segmentation:
Middle East and Africa anti-fungal agents market has been segmented on the basis of therapeutic indication which comprises into aspergillosis, dermatophytosis, candidiasis and others. On the basis of drug class; market is segmented into azoles, pyrimidines, echinocandins, polyenes, allylamines, and others. On the basis of route of administration; market is segmented into oral, local and others.